Recently, LNC received the EC (Ethics Committee) approval from the Beijing Hospital regarding the 18F-LNC1001 Injection and will conduct the Phase III clinical trial in the near future.

In Jul. 2022, LNC has received the IND approval from the NMPA (National Medical Products Administration) for the 18F-LNC1001 Injection Phase I clinical trial.

—— About 18F-LNC1001 Injection ——

18F-LNC1001 injection is a PSMA-targeted radionuclide diagnostic drug, registered as Class 1 chemical drugs. Currently entered Phase III clinical trial. Suitable for positron emission tomography (PET) imaging of PSMA- positive prostate cancer patients as follows: patients who are suspected of metastases after initial radical treatment; patients with elevated serum prostate specific antigen (PSA) levels and suspected to have biochemical recurrence. The targeting specificity of PSMA enables the delivery of radionuclide fluorine [18F] to lesion sites of PSMA- positive prostate cancer, by using PET imaging to achieve the diagnostic purpose.

LNC was jointly founded by DC PHARMA and Professor Chen Xiaoyuan, a top expert in molecular imaging and nanomedicine, in 2021. Adhering to the concept of "Innovation-driven Micro Radiotheranostics R&D, Benefit People from Precision Therapy", LNC is focusing on the construction of a globally leading integrated diagnosis and therapy innovation platform on cancer nuclear medicine R&D. Next, LNC will continue to rely on DC PHARMA's strong and sound production and research system for the entire nuclear medicine industry chain, strengthen innovation, providing precision diagnosis and therapeutic methods for cancer patients and promoting the development of nuclear medicine in the world.